Purpose
|
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
|
Characteristics
|
Tradename: XALKORI Source of Compound: synthetic Target: TGF-beta/Smad inhibitor,c-MET inhibitor Receptor: ALK ,c-MET Status: USP
|
Purification
|
All the products are sent with COA, HPLC and NMR inspection report to guarantee the quality.
|
Purity
|
99?% +
|
Formula
|
C21H22Cl2FN5O
|
Solubility
|
DMSO 9 mg/mL,Water <1 mg="" ml="" <="" td="">
1> |